Document Detail


Maintenance of intragastric pH > 4 with famotidine in duodenal ulcer patients: factors influencing drug requirements.
MedLine Citation:
PMID:  8020798     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The gastrojet, a closed loop pH feedback infusion pump capable of maintaining intragastric pH at a target value by infusing H2 blockers at variable rates, was used to assess factors influencing the quantity of famotidine required to maintain intragastric pH above 4 for 24 hours in 34 fed patients with duodenal ulcers. The following factors were considered: sex, age, duration of the disease, previous bleeding, previous poor response to H2 blockers (ulcer unhealed at six weeks, or recurrence within three months during maintenance treatment), activity of the ulcer disease, smoking habits, cirrhosis. The patients had taken no antisecretory drugs for the 15 days before the study. Two standardised meals were given during the study period (from 1000 to 1000). Fifty ml of famotidine (4 mg/ml) was loaded into infusion bags and the pump was programmed to deliver the drug intravenously at 11 rates varying from 0 to 40 microliters/min. The target pH was 4. Mean famotidine use was 111 mg (range 33 to 200), the 23 hour median pH was 5.3, and the mean time during which pH was above 4 was 75.4%. There was a negative correlation (p < 0.001) between famotidine delivery and the inhibition of gastric acidity. Statistical analysis showed that only cirrhosis significantly influenced drug delivery, median pH, and the time during which pH was above 4. Mean drug delivery in the cirrhotic and non-cirrhotic patients was 135 v 97 mg (p < 0.04), 23 hour median pH was 4.7 v 5.6 (p < 0.01), and the mean time at pH > 4 was 65.9 v 81.6% (p < 0.01). There were large interindividual variations in famotidine requirements, but not only cirrhosis was predictive of dose requirement. These results suggest that the appropriate amount of famotidine to treat duodenal ulcer in cirrhotic patients is probably higher than the usually recommended dose.
Authors:
J C Delchier; F Roudot-Thoraval; L Stanescu; M C Deharvengt; L Elouaer Blanc
Related Documents :
1976298 - Prolonged benefit in the treatment of chronic idiopathic urticaria with astemizole.
3898348 - Ranitidine versus anticholinergic/antacid for duodenal ulcer. a randomized, endoscopica...
1993488 - Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer rela...
2735328 - A maintenance regimen of sucralfate 2 g at night for reduced relapse rate in duodenal u...
10614608 - Complex regional pain syndrome of the lower extremity: a retrospective study of 33 pati...
24949728 - Comparison of conventional tacrolimus versus prolong release formula as initial therapy...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Gut     Volume:  35     ISSN:  0017-5749     ISO Abbreviation:  Gut     Publication Date:  1994 Jun 
Date Detail:
Created Date:  1994-08-03     Completed Date:  1994-08-03     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  2985108R     Medline TA:  Gut     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  750-4     Citation Subset:  AIM; IM    
Affiliation:
Unité INSERM 99, Hôpital Henri Mondor, Créteil, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Drug Delivery Systems
Duodenal Ulcer / drug therapy*
Duodenum / pathology
Famotidine / administration & dosage,  therapeutic use*
Female
Fibrosis
Gastric Acid / secretion
Humans
Hydrogen-Ion Concentration
Male
Middle Aged
Time Factors
Chemical
Reg. No./Substance:
76824-35-6/Famotidine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bleeding peptic ulcer--risk factors for rebleeding and sequential changes in endoscopic findings.
Next Document:  Effects of Helicobacter pylori on histamine and carbachol stimulated acid secretion by human parieta...